Dose Modifications and Supportive Care
toxicity, Anemia, anemia
ANEMIA, EVENT, ADVERSE EVENT, ANEMIA
In the event of a grade 3 or greater toxicity, daily dosing was interrupted. Upon resuming treatment, talazoparib was administered at the next lower dose level (reduced increments of 0.25 mg/day). Twenty (32.8%) patients had AEs leading to dose interruptions and 24 (39.3%) had AEs leading to dose reductions (Dose modifications and permanent drug discontinuation (ITT population).Abbreviations: AE, adverse event; ITT, intent-to-treat.

Anemia is a known AE for talazoparib. In this study, 24 patients (39.3%) experienced treatment-related grade 3 anemia (